IL15 and hematologic disorder: IL15 and some of its derivatives (i.e., NIZ985; ALT-803; Receptor-Linker-IL15, RLI) has been investigated in different clinical trials, with preliminary data suggesting its role as a single agent, or in cellular treatment approaches for solid and hematological malignancies, including CLL [17,18,19].